trending Market Intelligence /marketintelligence/en/news-insights/trending/vv2UTpzoKofD_jPEzPqbgg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Incyte's application for bile duct cancer drug accepted by EU

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Incyte's application for bile duct cancer drug accepted by EU

The European Medicines Agency has accepted Incyte Corp.'s application seeking approval of pemigatinib to treat a rare type of cancer that forms in the bile duct.

Wilmington, Del.-based Incyte is seeking approval for pemigatinib to treat adults with cholangiocarcinoma that has spread to nearby tissues or to other parts of the body. Cholangiocarcinoma is a rare form of cancer that develops in the bile ducts that connect the liver to the gallbladder and small intestine.

Incyte's therapy is meant for patients with this type of cancer who have a certain gene mutation of the fibroblast growth factor receptor 2 gene and whose cancer is either treatment-resistant or has relapsed after at least one prior cancer therapy.

The company said the marketing authorization application is backed by data from a phase 2 study called Fight-202, which showed that 36% of patients with the gene mutation who received the drug showed a reduction in their tumor size.

The new drug application for pemigatinib was granted priority review for the same indication in the U.S. on Nov. 27, 2019. The U.S. Food and Drug Administration is expected to make a decision around May 30.